123 related articles for article (PubMed ID: 18769130)
21. DNA methylation in ductal carcinoma in situ of the breast.
Pang JM; Dobrovic A; Fox SB
Breast Cancer Res; 2013 Jun; 15(3):206. PubMed ID: 23826974
[TBL] [Abstract][Full Text] [Related]
22. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation.
Krassenstein R; Sauter E; Dulaimi E; Battagli C; Ehya H; Klein-Szanto A; Cairns P
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):28-32. PubMed ID: 14734448
[TBL] [Abstract][Full Text] [Related]
23. Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
Feng W; Shen L; Wen S; Rosen DG; Jelinek J; Hu X; Huan S; Huang M; Liu J; Sahin AA; Hunt KK; Bast RC; Shen Y; Issa JP; Yu Y
Breast Cancer Res; 2007; 9(4):R57. PubMed ID: 17764565
[TBL] [Abstract][Full Text] [Related]
24. RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
Sebova K; Zmetakova I; Bella V; Kajo K; Stankovicova I; Kajabova V; Krivulcik T; Lasabova Z; Tomka M; Galbavy S; Fridrichova I
Cancer Biomark; 2011-2012; 10(1):13-26. PubMed ID: 22297548
[TBL] [Abstract][Full Text] [Related]
25. Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women.
Mehrotra J; Ganpat MM; Kanaan Y; Fackler MJ; McVeigh M; Lahti-Domenici J; Polyak K; Argani P; Naab T; Garrett E; Parmigiani G; Broome C; Sukumar S
Clin Cancer Res; 2004 Mar; 10(6):2052-7. PubMed ID: 15041725
[TBL] [Abstract][Full Text] [Related]
26. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
27. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
[TBL] [Abstract][Full Text] [Related]
28. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
29. Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ.
Davis JE; Nemesure B; Mehmood S; Nayi V; Burke S; Brzostek SR; Singh M
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):20-5. PubMed ID: 26317313
[TBL] [Abstract][Full Text] [Related]
30. Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS).
Geradts J; Groth J; Wu Y; Jin G
Breast Cancer Res Treat; 2016 Jun; 157(3):447-59. PubMed ID: 27250000
[TBL] [Abstract][Full Text] [Related]
31. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
[TBL] [Abstract][Full Text] [Related]
32. Concordance of DNA methylation profiles between breast core biopsy and surgical excision specimens containing ductal carcinoma in situ (DCIS).
Chen Y; Marotti JD; Jenson EG; Onega TL; Johnson KC; Christensen BC
Exp Mol Pathol; 2017 Aug; 103(1):78-83. PubMed ID: 28711544
[TBL] [Abstract][Full Text] [Related]
33. Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis.
Fleischer T; Frigessi A; Johnson KC; Edvardsen H; Touleimat N; Klajic J; Riis ML; Haakensen VD; Wärnberg F; Naume B; Helland A; Børresen-Dale AL; Tost J; Christensen BC; Kristensen VN
Genome Biol; 2014; 15(8):435. PubMed ID: 25146004
[TBL] [Abstract][Full Text] [Related]
34. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
35. Quantitative assessment of promoter hypermethylation during breast cancer development.
Lehmann U; Länger F; Feist H; Glöckner S; Hasemeier B; Kreipe H
Am J Pathol; 2002 Feb; 160(2):605-12. PubMed ID: 11839581
[TBL] [Abstract][Full Text] [Related]
36. Basal-like breast cancer displays distinct patterns of promoter methylation.
Lee JS; Fackler MJ; Lee JH; Choi C; Park MH; Yoon JH; Zhang Z; Sukumar S
Cancer Biol Ther; 2010 Jun; 9(12):1017-24. PubMed ID: 20505321
[TBL] [Abstract][Full Text] [Related]
37. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
[TBL] [Abstract][Full Text] [Related]
38. The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer.
Wang D; Li C; Zhang X
DNA Cell Biol; 2014 Sep; 33(9):581-90. PubMed ID: 24842653
[TBL] [Abstract][Full Text] [Related]
39. Loss of expression of the putative tumor suppressor NES1 gene in biopsy-proven ductal carcinoma in situ predicts for invasive carcinoma at definitive surgery.
Yunes MJ; Neuschatz AC; Bornstein LE; Naber SP; Band V; Wazer DE
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):653-7. PubMed ID: 12788170
[TBL] [Abstract][Full Text] [Related]
40. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
